Field of Application
Cellular proliferation assays are widely used and accepted in oncology as an initial screen in the transition phase from biochemical screens to biological relevant models. ProQinase's CL100-ProliFiler is a standard service package comprising IC50 determination of one test compound against a defined panel of 100 cell lines. In addition, ProQinase offers free choice cell proliferation assay services with definition of the number of test cpds and cell lines according to your requirements.
Our Service
CL100-ProliFiler
Free Choice Cell Proliferation Assays
# | Cell | Entity of Origin |
|---|---|---|
1 | J82 | Bladder |
2 | HL-60 | Blood/Leukemia |
3 | K562 | Blood/Leukemia |
4 | KARPAS 299 | Blood/Leukemia |
5 | KG1 | Blood/Leukemia |
6 | KG1a | Blood/Leukemia |
7 | KMS-12-BM | Blood/Leukemia |
8 | LP-1 | Blood/Leukemia |
9 | M07e | Blood/Leukemia |
10 | Molm-13 | Blood/Leukemia |
11 | MOLT4 | Blood/Leukemia |
12 | MV4-11 | Blood/Leukemia |
13 | NALM-6 | Blood/Leukemia |
14 | OCI-AML5 | Blood/Leukemia |
15 | OPM-2 | Blood/Leukemia |
16 | P31/FUJ | Blood/Leukemia |
17 | RPMI 8226 | Blood/Leukemia |
18 | RS4 11 | Blood/Leukemia |
19 | SU-DHL5 | Blood/Leukemia |
20 | U-266 | Blood/Leukemia |
21 | U-937 | Blood/Leukemia |
22 | WSU-NHL | Blood/Leukemia |
23 | Saos-2 EC | Bone |
24 | SJSA-1 | Bone |
25 | SK-ES-1 | Bone |
26 | U2OS | Bone |
27 | A172 | Brain |
28 | H4 | Brain |
29 | LN229 | Brain |
30 | SK-N-FI | Brain |
31 | SK-N-MC | Brain |
32 | SK-N-SH | Brain |
33 | U87MG | Brain |
34 | U118MG | Brain |
35 | BT-20 | Breast |
36 | HCC 1569 | Breast |
37 | HCC38 | Breast |
38 | JIMT-1 | Breast |
39 | MCF-7 | Breast |
40 | MDA MB 231 | Breast |
41 | MDA MB 468 | Breast |
42 | SK.BR-3 | Breast |
43 | T47D | Breast |
44 | ZR-75-1 | Breast |
45 | HCC202 | Breast |
46 | EFM-192A | breast |
47 | C33a | Cervix |
48 | HeLa | Cervix |
49 | SiHa | Cervix |
50 | Colo 205 | Colon |
51 | CX-1 | Colon |
52 | DLD-1 | Colon |
53 | HCT116 | Colon |
54 | HCT-15 | Colon |
55 | HT-29 | Colon |
56 | LOVO | Colon |
57 | LS174T | Colon |
58 | RKO | Colon |
59 | SW480 | Colon |
60 | SW620 | Colon |
61 | SW948 | Colon |
62 | T-84 | Colon |
63 | Caco-2 | Colon |
64 | Colo-320DM | Colon |
65 | Hutu 80 | Duodenum |
66 | HEC-1-B | Endometrium |
67 | Ichikawa | Endometrium |
68 | HEC-1-A | endometrium |
69 | HT-1080 | Fibrosarcoma |
70 | A498 | Kidney |
71 | Caki-1 | Kidney |
72 | Caki-2 | Kidney |
73 | HepG2 | Liver |
74 | Hep3B2.1-7 | Liver |
75 | A427 | Lung |
76 | A549 | Lung |
77 | Calu-6 | Lung |
78 | DV90 | Lung |
79 | H1299 | Lung |
80 | H460 | Lung |
81 | HCC827 | Lung |
82 | N417 | Lung |
83 | NCI-H1048 | Lung |
84 | NCI-H1437 | Lung |
85 | NCI-H1581 | Lung |
86 | NCI-H1703 | Lung |
87 | NCI-H2110 | Lung |
88 | NCI-H2286 | Lung |
89 | NCI-H292 | Lung |
90 | NCI-H441 | Lung |
91 | NCI-H838 | Lung |
92 | RERF-LC-MS | Lung |
93 | SCLC-21H | Lung |
94 | SK-LU-1 | Lung |
95 | BEN | lung |
96 | COR-L279 | lung |
97 | EPLC-272H | lung |
98 | LOU-NH91 | lung |
99 | NCI-H1563 | lung |
100 | NCI-H1573 | lung |
101 | NCI-H1838 | lung |
102 | NCI-H2009 | lung |
103 | RERF-LC-Ad2 | lung |
104 | COV434 | Ovary |
105 | EFO-27 | Ovary |
106 | MCAS | Ovary |
107 | NCI-ADR | Ovary |
108 | OV56 | Ovary |
109 | OVCAR-3 | Ovary |
110 | OVK18 | Ovary |
111 | RL95-2 | Ovary |
112 | SK-OV3 | Ovary |
113 | SNU840 | Ovary |
114 | AsPC-1 | Pancreas |
115 | BxPC3 | Pancreas |
116 | Mia PaCA2 | Pancreas |
117 | PANC-1 | Pancreas |
118 | DU-145 | Prostate |
119 | LnCap | Prostate |
120 | PC3 | Prostate |
121 | A2058 | Skin |
122 | A375 | Skin |
123 | A431 | Skin |
124 | MDA MB 435 | Skin |
125 | SK-MEL-3 | Skin |
126 | Hs 746T | Stomach |
127 | MKN-1 | Stomach |
128 | MKN-45 | Stomach |
129 | NCI-N87 | Stomach |
130 | SCH | Stomach |
131 | SNU-1 | Stomach |
Infos in Brief
-
CL100-ProliFiler Slots 2017
-
Testing will start on: June 05 // September 04 // November 27
-
Cpd Exposure
-
72 h
-
Readout
-
CellTiter-Glo® Luminescent
-
Testing Formats
-
IC50 (8 semi-log dilutions in duplicate)
-
Cpd Submission
-
Solved or as pre-weighed powder
-
Tolerable Solvent
-
Max 0.1 % DMSO
-
Reference Cpd
-
Bortezomib
-
Report
-
Comprehensive evaluation of data including raw data for own analysis
-
Related Publication from ProQinase
-
Summary Sheet